554 related articles for article (PubMed ID: 19632113)
21. [Synthesis and biological evaluation of 3-quinolinecarbonitrile-7-amide derivatives].
Liu B; You QD; Li ZY
Yao Xue Xue Bao; 2009 Aug; 44(8):879-84. PubMed ID: 20055156
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles.
Boschelli DH; Wang YD; Ye F; Wu B; Zhang N; Dutia M; Powell DW; Wissner A; Arndt K; Weber JM; Boschelli F
J Med Chem; 2001 Mar; 44(5):822-33. PubMed ID: 11262092
[TBL] [Abstract][Full Text] [Related]
24. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
Zhu GD; Gong J; Claiborne A; Woods KW; Gandhi VB; Thomas S; Luo Y; Liu X; Shi Y; Guan R; Magnone SR; Klinghofer V; Johnson EF; Bouska J; Shoemaker A; Oleksijew A; Stoll VS; De Jong R; Oltersdorf T; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem Lett; 2006 Jun; 16(12):3150-5. PubMed ID: 16603355
[TBL] [Abstract][Full Text] [Related]
25. 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.
Spicer JA; Rewcastle GW; Kaufman MD; Black SL; Plummer MS; Denny WA; Quin J; Shahripour AB; Barrett SD; Whitehead CE; Milbank JB; Ohren JF; Gowan RC; Omer C; Camp HS; Esmaeil N; Moore K; Sebolt-Leopold JS; Pryzbranowski S; Merriman RL; Ortwine DF; Warmus JS; Flamme CM; Pavlovsky AG; Tecle H
J Med Chem; 2007 Oct; 50(21):5090-102. PubMed ID: 17880056
[TBL] [Abstract][Full Text] [Related]
26. Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.
Traquandi G; Ciomei M; Ballinari D; Casale E; Colombo N; Croci V; Fiorentini F; Isacchi A; Longo A; Mercurio C; Panzeri A; Pastori W; Pevarello P; Volpi D; Roussel P; Vulpetti A; Brasca MG
J Med Chem; 2010 Mar; 53(5):2171-87. PubMed ID: 20141146
[TBL] [Abstract][Full Text] [Related]
27. 7-(aryl/heteroaryl-2-ylethynyl)-4-phenylamino-3-quinolinecarbonitriles as new Src kinase inhibitors: addition of water solubilizing groups.
Wu B; Barrios Sosa AC; Boschelli DH; Boschelli F; Honores EE; Golas JM; Powell DW; Wang YD
Bioorg Med Chem Lett; 2006 Aug; 16(15):3993-7. PubMed ID: 16735116
[TBL] [Abstract][Full Text] [Related]
28. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
[TBL] [Abstract][Full Text] [Related]
29. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
30. Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.
Barrios Sosa AC; Boschelli DH; Wu B; Wang Y; Golas JM
Bioorg Med Chem Lett; 2005 Mar; 15(6):1743-7. PubMed ID: 15745832
[TBL] [Abstract][Full Text] [Related]
31. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase.
Mallon R; Feldberg L; Kim S; Collins K; Wojciechowicz D; Kohler C; Kovacs D; Discafani C; Zhang N; Wu B; Floyd B; Powell D; Berger D
Mol Cancer Ther; 2004 Jun; 3(6):755-62. PubMed ID: 15210862
[TBL] [Abstract][Full Text] [Related]
32. Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.
Sliman F; Blairvacq M; Durieu E; Meijer L; Rodrigo J; Desmaële D
Bioorg Med Chem Lett; 2010 May; 20(9):2801-5. PubMed ID: 20363627
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Plé PA; Green TP; Hennequin LF; Curwen J; Fennell M; Allen J; Lambert-Van Der Brempt C; Costello G
J Med Chem; 2004 Feb; 47(4):871-87. PubMed ID: 14761189
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective profile of novel SRC kinase inhibitors in rodent models of cerebral ischemia.
Liang S; Pong K; Gonzales C; Chen Y; Ling HP; Mark RJ; Boschelli F; Boschelli DH; Ye F; Barrios Sosa AC; Mansour TS; Frost P; Wood A; Pangalos MN; Zaleska MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):827-35. PubMed ID: 19741150
[TBL] [Abstract][Full Text] [Related]
35. Design of selective, ATP-competitive inhibitors of Akt.
Freeman-Cook KD; Autry C; Borzillo G; Gordon D; Barbacci-Tobin E; Bernardo V; Briere D; Clark T; Corbett M; Jakubczak J; Kakar S; Knauth E; Lippa B; Luzzio MJ; Mansour M; Martinelli G; Marx M; Nelson K; Pandit J; Rajamohan F; Robinson S; Subramanyam C; Wei L; Wythes M; Morris J
J Med Chem; 2010 Jun; 53(12):4615-22. PubMed ID: 20481595
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
[TBL] [Abstract][Full Text] [Related]
37. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers.
Kemnitzer W; Sirisoma N; May C; Tseng B; Drewe J; Cai SX
Bioorg Med Chem Lett; 2009 Jul; 19(13):3536-40. PubMed ID: 19464890
[TBL] [Abstract][Full Text] [Related]
39. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
40. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.
Wallace EM; Lyssikatos J; Blake JF; Seo J; Yang HW; Yeh TC; Perrier M; Jarski H; Marsh V; Poch G; Livingston MG; Otten J; Hingorani G; Woessner R; Lee P; Winkler J; Koch K
J Med Chem; 2006 Jan; 49(2):441-4. PubMed ID: 16420026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]